Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab/Chemotherapy With MO-03 in Early Stage TNBC
NCT07552181Phase 2Not yet recruiting
- Sponsor
- Yuanyuan Biotech
- Start
- Sep 2026
- Primary completion
- Sep 2035
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of MO-03 in triple-negative breast cancer (TNBC), sponsored by Yuanyuan Biotech. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MO-03
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07552181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552181.